Patient-reported outcomes in patients with resected, stage III BRAF V600+melanoma treated with adjuvant dabrafenib plus trametinib: COMBI-APlus study
Authors
Grob, J. J.Dutriaux, C.
Del Vecchio, M.
Ryll, B.
Robert, C.
Gogas, H. J.
Menzies, A. M.
Gupta, Avinash
Banerjee, H.
Lau, M. R.
Atkinson, V. G.
Affiliation
Department Of Dermatology And Skin Cancers, Timone Hospital AP-HM, Aix-Marseille University, 13385Issue Date
2022
Metadata
Show full item recordCitation
Grob JJ, Dutriaux C, Del Vecchio M, Ryll B, Robert C, Gogas HJ, et al. Patient-reported outcomes in patients with resected, stage III BRAF V600+melanoma treated with adjuvant dabrafenib plus trametinib: COMBI-APlus study. Annals of Oncology. 2022 Sep;33(7):S911-S2. PubMed PMID: WOS:000866211601074.Journal
Annals of OncologyDOI
10.1016/annonc/annonc1059Additional Links
https://dx.doi.org/10.1016/annonc/annonc1059Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/annonc/annonc1059